Mar 29, 2022 7:00am EDT SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Mar 24, 2022 8:30am EDT SCYNEXIS to Report Fourth Quarter and Full Year 2021 Financial Results and Provide a Business Update
Mar 08, 2022 8:30am EST SCYNEXIS Named to Fast Company’s 2022 List of the World’s Most Innovative Companies
Feb 10, 2022 7:36am EST SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
Dec 20, 2021 8:30am EST BREXAFEMME® (ibrexafungerp tablets) Added to Major National Formulary, Providing Access for Millions More Commercially Insured Patients
